The global C-reactive protein (CRP) testing market was valued at USD 5.27 billion in 2024 and is expected to reach USD 6.08 billion by 2033, registering a CAGR of 1.64% from 2025 to 2033. Market growth is primarily driven by the rising demand for precision medicine and the increasing clinical importance of CRP as an early biomarker of inflammation. CRP is an acute-phase protein that shows elevated levels during the initial stages of disease, making it a critical tool for early diagnosis and disease monitoring.The growing prevalence of chronic conditions such as cardiovascular diseases, diabetes, and autoimmune disorders continues to support market expansion. Additionally, advancements in CRP diagnostic technologies, including improved assay sensitivity, enhanced accuracy, and greater accessibility of testing solutions, are further strengthening market adoption across healthcare settings.
Key Market Trends & Insights
• North America dominated the global CRP testing market, accounting for 40.89% of total revenue in 2024.
• The U.S. held the largest revenue share within North America in 2024.
• By assay type, the immunoturbidimetric assay segment led the market with a 48.46% revenue share in 2024.
• Based on detection range, the hs-CRP segment captured 61.82% of the revenue share in 2024.
• By disease indication, the rheumatoid arthritis segment accounted for 25.87% of market revenue in 2024.
• Among end users, hospitals held the largest share at 38.29% in 2024, while clinics are expected to grow at the fastest rate over the forecast period.
Market Size & Forecast
• 2024 Market Size: USD 5.27 Billion
• 2033 Projected Market Size: USD 6.08 Billion
• CAGR (2025–2033): 1.64%
• Largest Market (2024): North America
Key C-Reactive Protein Testing Company Insights
The market is characterized by active participation from established diagnostic companies focused on advancing CRP testing technologies. Leading players are investing in research and development, product innovation, and strategic collaborations to expand their product portfolios and geographic reach. Market participants are also pursuing mergers, acquisitions, and regulatory approvals to maintain competitiveness and strengthen their market presence.
Key C-Reactive Protein Testing Companies
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher
• Quest Diagnostics
• Siemens Healthineers AG
• Abbott
• Merck KGaA
• Zoetis
• Ortho Clinical Diagnostics
• Getein Biotech, Inc.
• HORIBA, Ltd
• Randox Laboratories Ltd.
• Boditech Med, Inc.
• Aidian
Order a free sample PDF of the C-reactive Protein Testing Market Intelligence Study, published by Grand View Research.